TSHA Taysha Gene Therapies Inc

TSHA-102 in clinical evaluation for Rett syndrome: Cohort one data from the REVEAL Phase 1/2 Adolescent-Adult and Pediatric trials June 18, 2024 Exhibit 99.2

Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, prospects, plans and objectives of management, the potential of TSHA-102, the anticipated timelines for reporting data for the TSHA-102 REVEAL trials and the trial design of the TSHA-102 REVEAL trials are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Risks regarding our business are described in detail in our Securities and Exchange Commission filings, including in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the SEC, which are available on the SEC’s website at www.sec.gov . We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements contained in this presentation reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. All of the market data used in this prospectus involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.

Key Takeaway: Encouraging safety profile and improvements across consistent clinical domains in all four patients treated with the low dose of TSHA-102 support the transformative potential of TSHA-102 No serious adverse events (SAEs) related to TSHA-102 or dose-limiting toxicities (DLTs) observed Early improvements demonstrated, and sustained through longer-term assessments Motor skills Communication/socialization Autonomic function Seizures Improvements across multiple clinical domains Improvements across multiple efficacy measures Generally well-tolerated Improvements across consistent clinical domains in adult and pediatric patients with different genetic mutation severity support broad treatment potential of TSHA-102 Adolescent/adult trial: based on week 52 safety and efficacy data for patient one, and week 36 safety data and week 25 efficacy data for patient two. Pediatric trial: based on week 22 safety data and week 12 efficacy data for patient one, and week 11 safety data and week 8 efficacy data for patient two.

Rett syndrome: a rare, progressive neurodevelopmental disease with high unmet medical need Caused by mutations in the X-linked gene encoding MeCP21 Leads to impaired brain development and function Primarily occurs in females Symptoms and severity vary due in part to  random X-inactivation2 Significant market opportunity Estimated prevalence of typical Rett syndrome caused by a MECP2 mutation is between 15,000 and 20,000 patients in major global markets (U.S., EU+U.K.)3 Rett syndrome occurs worldwide in 1 of every 10,000 female births3 Sources: 1Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185-188. 2Braunschweig D, Simcox T, Samaco RC, LaSalle JM. X-Chromosome inactivation ratios affect wild-type MeCP2 expression within mosaic Rett syndrome and Mecp2-/+ mouse brain. Hum Mol Genet. 2004;13(12):1275-1286. 3IRSF; NORD; Amir RE, Van den Veyver IB, Wan M, et al. Rett Syndrome Is Caused by Mutations in X-Linked Mecp2, Encoding Methyl-Cpg-Binding Protein 2. Nat Genet 232:185-188. 1999.

TSHA-102: an investigational one-time gene therapy for Rett syndrome that is designed to regulate MECP2 on a cell-by-cell basis TSHA-102 delivers a functional form of MECP2 to cells in the central nervous system (CNS) Equipped with novel miRNA-responsive target sequence (miRARE) designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis to minimize risk of overexpression Senses transgene and endogenous MECP2 levels to provide a superior therapeutic profile to that of unregulated MECP2 gene replacement3 Delivered via intrathecal (IT) administration to target key CNS regions and minimize viral load using a routine, minimally invasive procedure in an outpatient setting Sources: 1Tillotson R et al. 2017 Nature; 550:398-401; Sinnett SE et al. A New Approach for Designing a Feedback-Enabled AAV Genome Improves Therapeutic Outcomes of MiniMeCP2 Gene Transfer in Mice Modeling RTT. 23rd Annual meeting for the American Society of Gene & Cell Therapy; April 28,2020. 2McCarty DM. Self-complementary AAV vectors: Advances and applications. Mol Ther. 2008;16(10):1648-1656. 3Haque E et al. The microRNA-responsive autoregulatory element from TSHA-102 for Rett Syndrome modulates therapeutic transgene expression in response to cellular MeCP2 in mouse and human cell lines. 30th Annual Congress of the European Society for Gene and Cell Therapy, 24–27 Oct 2023, Brussels, Belgium. Poster #P435. AAV9 capsid 2) 3) 1) 4) miniMECP2 allows for packaging of miRARE technology for sophisticated regulatory control in a self-complementary design1 Self-complementary technology enables more rapid transgene expression due to ability to bypass the rate-limiting second-strand synthesis in host cells2 MeP426 promoter allows targeted neuronal expression and capitalizes on endogenous transcriptional regulation in the brain Clinically and commercially proven across multiple CNS indications

Open-label, dose-escalation and dose-expansion, randomized, multi-center trial for TSHA-102 Clinical trial: NCT05606614; MAD: maximum administered dose; MTD: maximum tolerated dose Cohort 1 5.7x1014 total vg Cohort 2 1x1015 total vg Cohort 3 MAD/MTD  Part A: Dose Escalation Part B: Dose Expansion Adolescent and Adult REVEAL Phase 1/2 trial in U.S. and Canada First patient dosed in Q2 2024 Completed N=2 N=3 Study Overview Objectives Safety and preliminary efficacy of TSHA-102 Part A: evaluates two dose levels; if possible, establishes MAD or MTD  Part B: evaluates the MAD or MTD Key inclusion criteria Females aged 12+ with pathogenic confirmation of MECP2 mutation CGI-S score of ≥4 at screening Key clinical assessments Revised Motor Behavior Assessment Scale (R-MBA)  Clinical Global Impression Scale-Severity and Improvement (CGI-S and CGI-I) Parental Global Impressions Scale-Improvement (PGI-I) Rett Syndrome Behavior Questionnaire (RSBQ) Rett Syndrome Hand Function Scale (RSHFS)

Encouraging safety profile and improvements across consistent clinical domains observed through longer-term assessments in both adult patients in low dose cohort No SAEs related to TSHA-102 or DLTs as of week 52 assessment (patient one) and week 36 assessment (patient two) Generally well-tolerated Improvements across multiple efficacy measures Improvements across multiple clinical domains Sustained and new improvements at week 52 (patient one) and at week 25 (patient two) following completion of steroid taper  Principal Investigator reported sustained and new improvements across multiple domains including motor skills, communication/socialization, autonomic function and seizures at week 52 (patient one) and at week 25 (patient two) following completion of steroid taper Continued improvements observed in both adult patients with different genetic mutation severity and phenotypic expression support the durable response of TSHA-102

Both adult patients dosed in low dose cohort had stage four Rett syndrome with different genetic mutation severity and phenotypic expression Source: Company data | baseline characteristics based on pre-treatment observations, baseline assessments, pre-screening visits and patient’s medical history.  Baseline Characteristics Adult Patient One Adult Patient Two Diagnosed with stage four “late motor deterioration muscle wasting” Rett syndrome 20 year-old female 21 year-old female Large MECP2 deletion Missense MECP2 mutation Severe phenotype Milder phenotype “Severely ill” – CGI-S baseline score of 6 “Moderately ill” – CGI-S baseline score of 4  Motor Skills: Complete loss of ambulation and ability to sit unassisted; wheelchair-bound by age 8 Loss of hand function by age 6 Communication/Socialization: Mostly non-verbal by age 6 Autonomic Function: Frequent apnea and hyperventilation by age 3 Seizures: Seizures at age 5 (2-4 per year at baseline) Motor Skills: Partial loss of ambulation by age 2 Walks with impaired gait and balance by age 18 Hand stereotypies with weak grasping by age 3 Communication/Socialization: Mostly non-verbal by age 2 Autonomic Function: Frequent hyperventilation by age 3 Seizures: Seizures by age 10 (2-4 per week at baseline)

Sustained and new improvements seen across multiple clinical domains in both adult patients based on clinical observations reported by Principal Investigator Clinical Domain Improvements  Adult Patient One 52 weeks post-treatment  Completed steroid taper week 36 and sirolimus taper week 43 Adult Patient Two 25 weeks post-treatment Completed steroid taper week 25 and sirolimus taper week 31 Motor skills Improved hand function and gained ability to sit unassisted and move legs for the first time in over a decade  Improved hand stereotypies for the first time since regression at age three, and improved posture and stability Communication / Socialization Improved social interest, vocalization and use of eye-gaze driven communication device Improved social interest, including increased response to spoken words and eye contact Autonomic function Improved breathing patterns and circulation, and normalized sleep quality/duration with gained ability to sleep through night for the first time in 20 years Improved breathing patterns and circulation Seizures Stable seizure events with lower levels of anti-seizure medication relative to baseline  Significantly reduced seizure events with 25% lower levels of anti-seizure medication relative to baseline Seizure free for 8.5 months post-TSHA-102* Clinical observations made by the Principal Investigator are based on post-treatment assessments, pre-treatment observations, baseline assessments, pre-screening visits and patient’s medical history. Subject to change as the trial progresses. *Seizure data for adult patient two is based on Seizure Diary and caregiver reports as of week 36 post-TSHA-102

Sustained and new improvements seen across multiple clinical domains in both adult patients based on clinical observations from Principal Investigator Mostly non-verbal Adult Patient One 20-year-old female (large MECP2 deletion; severe phenotype) Seizures Complete loss of ambulation and ability to sit unassisted Apnea and hyperventilation Loss of hand function 52 weeks post-TSHA-102 AUTONOMIC FUNCTION: Improved breathing patterns and circulation, and normalized sleep quality/duration with gained ability to sleep through night for the first time in 20 years COMMUNICATION/SOCIALIZATION: Improved social interest, vocalization, and use of eye-driven communication device MOTOR FUNCTION: Improved hand function; gained ability to sit unassisted and move legs for the first time in over a decade SEIZURES: Stable seizure events with lower levels of anti-seizure medication relative to baseline Age 20 Age 5 Age 6 Age 8 Age 6 Age 3 Adult Patient Two 21-year-old female (missense MECP2 mutation; milder phenotype) Seizures Hand stereotypies with weak grasp Bradykinesia, walks with impaired gait and balance Frequent hyperventilation Partial loss of ambulation, mostly non-verbal Patient history 25 weeks post-TSHA-102 AUTONOMIC FUNCTION: Improved breathing patterns and circulation COMMUNICATION/SOCIALIZATION: Improved social interest MOTOR FUNCTION: Improved hand stereotypies for the first time since regression at age three and improved posture and stability SEIZURES: Significantly reduced seizure events with 25% lower levels of anti-seizure medication relative to baseline; seizure free for 8.5 months* Age 21 Age 3 Age 2 Age 18 Age 10 Age 3 Patient history Clinical observations made by the Principal Investigator are based on post-treatment assessments, pre-treatment observations, baseline assessments, pre-screening visits and patient’s medical history. Subject to change as the trial progresses. *Seizure data for adult patient two is based on Seizure Diary and caregiver reports as of week 36 post-TSHA-102

Clinical improvements demonstrated across multiple efficacy measures in both adult patients treated with TSHA-102 (low dose, 5.7x1014 total vg) Data presented reflects current data in the Electronic Data Capture System, subject to change   CGI-S CGI-I, with Rett anchors PGI-I RSBQ R-MBA RSHFS RSHFS Scale Description Clinician-reported 7-point assessment of illness severity 1=normal 7=among the most extremely ill Clinician-reported 7-point assessment of overall improvement 1=very much improved 7=very much worse Caregiver-reported 7-point assessment of overall improvement 1=considerably better 7=very much worse Caregiver-reported 45-item questionnaire to assess Rett syndrome characteristics Higher scores indicate greater severity Clinician-reported 24-question scale measuring disease behaviors of Rett syndrome Higher scores indicate greater severity Clinician-reported assessment of hand function in Rett syndrome by an independent experienced physical therapist, being reported as best score for large objects 1=no active grasping 4=independent grasp P1 P2 P1 P2 P1 P2 P1 P2 P1 P2 P1 P2 Screening, Baseline 6 Severely ill 4 Moderately ill - - - - 52 37 43 38 DH: 3 NH: NA* DH: NE* NH: 1 Week 4 5 Markedly ill 4 Moderately ill 2 Much improved 3 Minimally improved 3 A little better 3 A little better 29 33 48 31 DH: NE* NH: 1 Week 8 5 Markedly ill 4 Moderately ill 2 Much improved 3 Minimally improved 3 A little better 3 A little better 27 33 51 24 DH: 2 NH: 1 DH: 4 NH: 1 Week 12 5 Markedly ill 4 Moderately ill 2 Much improved 3 Minimally improved 2 Much better* 3 A little better 30 35 37 21 DH: 3 NH: 3* DH: NE* NH: 1 Week 25 5 Markedly ill 4 Moderately ill 2 Much improved 3 Minimally improved 2 Much better 3 A little better 22 39 42 15 DH: 3 NH: 2 DH: 4 NH: 1 Week 52 5 Markedly ill 3 Minimally improved 1 Considerably better 17 26 Overall Change + = + + + + + – + + + = *PGI-I week 12 assessment for patient one was captured at week 16; RSHFS week 12 assessment for patient one was captured on week 11; RSHFS assessment for patient one was not conducted at baseline; RSHFS assessment for patient two’s DH was not conducted as defined in the guidelines at baseline, week 4 and week 12, therefore the data is not evaluable at these time points. DH = dominant hand; NH = non-dominant hand; = not assessed; NE = not evaluable = improvement from baseline = no change from baseline = decline from baseline

Open-label, dose-escalation and dose-expansion, randomized, multi-center trial for TSHA-102 Study Overview Objectives Safety and preliminary efficacy of TSHA-102 Part A: evaluates two dose levels; if possible, establishes the MAD or MTD Part B: evaluates the MAD or MTD in two age cohorts Key inclusion criteria Females 5-8 years old with pathogenic confirmation of MECP2 mutation (Part A) CGI-S score of ≥4 at screening Key clinical assessments R-MBA CGI-S and CGI-I PGI-I RSBQ Adapted Mullen Scales for Early Learning (MSEL-A) Clinical trial: NCT06152237 Cohort 1 5.7x1014 total vg 5-8 years old Cohort 2 1x1015 total vg 5-8 years old  Cohort 3 MAD/MTD 5-8 years old   Part A: Dose Escalation Part B: Dose Expansion Cohort 4 MAD/MTD 3-5 years old   Pediatric REVEAL Phase 1/2 trial in the U.S. and U.K. Dosing of first patient expected in Q3 2024 N=3 N=2 Completed

Encouraging safety profiles and initial clinical improvements observed across multiple domains in first two pediatric patients dosed in low dose cohort No SAEs related to TSHA-102 or DLTs as of week 22 assessment (patient one) and week 11 assessment (patient two)* Generally well-tolerated Improvements across multiple efficacy measures Improvements across multiple clinical domains Early improvement demonstrated across multiple efficacy measures at week 12 (patient one) and at week 8 (patient two) Principal Investigator reported improvements across multiple domains including motor skills, communication/socialization, autonomic function and seizures at week 12 (patient one) and at week 8 (patient two) Early improvements observed in similar areas of disease with early evidence of developmental gains in pediatric patients with different genetic mutation severity and phenotypic expression *There were two SAEs reported in the second pediatric patient that were not deemed treatment-related – both were related to underlying disease, and one was also attributed to immunosuppression, and have both resolved.

First two pediatric patients with stage three Rett syndrome in low dose cohort had different genetic mutation severity and phenotypic expression Baseline Characteristics Pediatric Patient One Pediatric Patient Two Diagnosed with stage three “pseudo stationary” Rett syndrome 6 year-old female 7 year-old female MECP2 deletion Missense MECP2 mutation Moderate phenotype Milder phenotype “Markedly ill” – CGI-S baseline score of 5 “Moderately ill” – CGI-S baseline score of 4  Motor Skills: Non-ambulatory Sits unassisted for 30 seconds/stands with support by age 3 Impaired hand function by age 1.5 Communication/Socialization: Mostly non-verbal by age 1 Autonomic Function: Breath holding Seizures: Seizures by age 3 (1 seizure every 3 months at baseline) Motor Skills: Partial loss of ambulation by age 1.5 Impaired hand function by age 1 Communication/Socialization: Non-verbal by age 1 Autonomic Function: Frequent hyperventilation by age 4 Seizures: Seizures by age 3 (2-4 seizures daily at baseline) Source: Company data | baseline characteristics based on pre-treatment observations, baseline assessments, pre-screening visits and patient’s medical history. 

Clinical observations made by the Principal Investigator are based on post-treatment assessments, pre-treatment observations, baseline assessments, pre-screening visits and patient’s medical history. Subject to change as the trial progresses. Improvements seen across multiple clinical domains in both pediatric patients based on clinical observations reported by Principal Investigator Clinical Domain Improvements  Pediatric Patient One 12 weeks post-treatment  Pediatric Patient Two 8 weeks post-treatment  Motor skills Improved hand function and grasping with ability to hold object up to 3 minutes vs 12 seconds at baseline Improved truncal stability and balance with gained ability to move her leg on her own to better take a step with assistance and sit unassisted for longer duration  Improved swallowing and oral intake relative to gastrostomy tube feeding Improved hand function with ability to reach more quickly  Improved gait, speed and stability when walking with new skills gained including the gained ability to stand up from a chair and walk up a stair Communication / Socialization Improved use of eye-gaze driven communication device with new words communicated and gained ability to string multiple words together and identify object functions through device New skills gained in visual reception and receptive language Improved social interest and eye contact Autonomic function Improved breathing patterns Improved breathing patterns Seizures Stable seizure events relative to baseline Increase in days reported seizure-free since dosing; a new anti-seizure medication was added to regimen week 4, which has been maintained through week 11

Early evidence of developmental gains in both pediatric patients based on clinical data and observations from Principal Investigator Pediatric Patient One 6-year-old female (MECP2 deletion; moderate phenotype) Patient history 12 weeks post-TSHA-102 AUTONOMIC FUNCTION: Improved breathing patterns COMMUNICATION/SOCIALIZATION: Improved communication and use of eye-gaze driven communication device; gained new visual reception and receptive language skills MOTOR SKILLS: Improved hand function/grasping with ability to hold object up to 3 minutes; improved truncal stability and balance with gained ability to move leg to take step on own without assistance and sit unassisted for longer duration SEIZURES: Stable seizure events relative to baseline Age 6 Clinical observations made by the Principal Investigator are based on post-treatment assessments, pre-treatment observations, baseline assessments, pre-screening visits and patient’s medical history. Subject to change as the trial progresses. *A new anti-seizure medication was added to patient two’s regimen week 4, which has been maintained through week 11 Pediatric Patient Two 7-year-old female (missense MECP2 mutation; milder phenotype) Seizures Impaired hand function Mostly non-verbal Partial loss of ambulation Patient history 8 weeks post-TSHA-102 AUTONOMIC FUNCTION: Improved breathing patterns COMMUNICATION/SOCIALIZATION: Improved social interest and eye contact MOTOR SKILLS: Improved hand function with ability to reach more quickly; improved gait, speed and stability when walking with new skills gained including the ability to stand up from a chair and walk up a stair SEIZURES: Significantly reduced seizure frequency relative to baseline, with most days reported seizure-free* Age 7 Age 1 Age 1 Age 3 Age 1.5 Hyperventilation Age 4 Seizures Impaired hand function Mostly non-verbal Non-ambulatory: Sits unassisted for 30 seconds/stands with support Age 1.5 Age 3 Age 1 Age 3

  CGI-S CGI-I, with Rett anchors PGI-I RSBQ R-MBA MSEL-A RSHFS Scale Description Clinician-reported 7-point assessment of illness severity 1=normal 7=among the most extremely ill Clinician-reported 7-point assessment of overall improvement 1=very much improved 7=very much worse Caregiver-reported 7-point assessment of overall improvement 1=very much improved 7=very much worse Caregiver-reported 45-item questionnaire to assess Rett syndrome characteristics Higher scores indicate greater severity Clinician-reported 24-question scale measuring disease behaviors of Rett syndrome Higher scores indicate greater severity Clinician-reported 4 subscale scores to assess cognitive function for visual reception (VR), receptive language (RL), expressive language (EL) and fine motor (FM) Higher score indicates improvement P1 P2 P1 P2 P1 P2 P1 P2 P1 P2 P1 P2 Screening, Baseline 5 Markedly ill 4 Moderately ill – – – – 37 40 41 VR: 22 RL: 21 EL: 8 FM: 5 VR: 33 RL: 15 EL: 8 FM: 9 Week 4 5 Markedly ill 4 Moderately ill 3 Minimally improved 3 Minimally improved 3 A little better 3 A little better 41 50 35 Week 8 5 Markedly ill 4 Moderately ill 3 Minimally improved 2 Much improved 3 A little better* 2 Much better 36* 37* 30 30 Week 12 5 Markedly ill 3 Minimally improved 3 A little better 44 36 VR: 23 RL: 27 EL: 8 FM: 9 Overall Change = = + + + + – + + + + Data presented reflects current data in the Electronic Data Capture System, subject to change Clinical improvements demonstrated across multiple efficacy measures in both pediatric patients treated with TSHA-102 (low dose, 5.7x1014 total vg) = not assessed = improvement from baseline = no change from baseline = decline from baseline *Patient one’s RSBQ and R-MBA week 8 assessment was collected week 11; patient two’s RSBQ improvement at week 8 is compared to week 4 score as baseline RSBQ was not captured

MSEL-A: Pediatric patient one showed new developmental gains in visual reception, receptive language and fine motor skills at week 12 Adapted Mullen Scales of Early Learning (MSEL-A): Standardized cognitive developmental assessment adapted for patients with Rett syndrome that functionally evaluates skills compared to developmental milestones New developmental gains demonstrated at week 12 post-TSHA-102: VR: Gained ability to identify an object from memory RL: Gained ability to follow two unrelated commands and identify the function of objects and action words FM: Gained ability to use a refined thumb grasp  Per medical history and as reported by caregiver, the patient was not able to demonstrate these skills before treatment. Improvement in age equivalence of skills demonstrated in visual reception (VR), fine motor (FM) and receptive language (RL) at week 12 post-TSHA-102 Clarkson T, LeBlanc J, DeGregorio G, Vogel-Farley V, Barnes K, Kaufmann WE, Nelson CA. Adapting the Mullen Scales of Early Learning for a Standardized Measure of Development in Children With Rett Syndrome. Intellect Dev Disabil. 2017 Dec;55(6):419-431. doi: 10.1352/1934-9556-55.6.419. PMID: 29194024. Baseline Week 12

Improvements across consistent clinical domains in all patients treated with low-dose TSHA-102 based on clinician and caregiver assessments and video evidence

Progress in clinical-stage TSHA-102 program supports clinical evaluation across a broad range of ages and stages of Rett syndrome Completed dosing of Cohort 1 (low dose, n=2); encouraging longer-term safety and efficacy data* Expanded trial to include patients ≥12 years of age Dosed first patient in cohort two (high dose) following IDMC approval of Company’s request to dose escalate early RMAT, ODD, RPDD and FTD from U.S. FDA Adolescent & Adult REVEAL Phase 1/2 Trial in U.S. and Canada Pediatric REVEAL Phase 1/2 Trial in U.S. and U.K. Completed dosing of Cohort 1 (low dose, n=2); encouraging initial safety and efficacy data*  IDMC approved Company’s request to dose escalate early with dosing of first pediatric patient in cohort two (high dose) to follow IDMC review of initial safety data from first high dose patient in adolescent/adult trial RMAT, ODD, RPDD and FTD from U.S. FDA, ODD from E.U. EMA and ILAP designation from U.K. MHRA 2024: expect significant clinical data in adult, adolescent and pediatric patients at low and high dose across multiple geographies  *Adolescent/adult trial: based on week 52 safety and efficacy data for patient one, and week 36 safety data and week 25 efficacy data for patient two. Pediatric trial: based on week 22 safety data and week 12 efficacy data for patient one, and week 11 safety data and week 8 efficacy data for patient two. IDMC=Independent Data Monitoring Committee; RMAT=regenerative medicine advanced therapy designation; ODD=Orphan Drug designation; RPDD=Rare Pediatric Disease designation; FTD=Fast Track designation; FDA=Food and Drug Administration; E.U.=European Union; EMA=European Medicines Agency; ILAP=Innovative Licensing and Access Pathway designation; U.K.=United Kingdom; MHRA=Medicines and Healthcare products Regulatory Agency 

Third quarter of 2024 Dose first patient in cohort two (high dose, n=3) of 1x1015 total vg in REVEAL Phase 1/2 pediatric trial Second half of 2024 Report initial safety and efficacy data from cohort two (high dose) of 1x1015 in both REVEAL trials Anticipated TSHA-102 2024 program milestones

Q&A

Thank You investors@tayshagtx.com

Appendix

Safety summary and relatedness assessments In these clinical trials, TSHA-102 has been well-tolerated, with a total of 34** treatment-emergent adverse events (TEAEs). Of these, 33 were mild or moderate.  One serious adverse event (SAE), seizure (severe, grade 3), has been reported, unrelated to TSHA-102. This patient has a medical history of seizures requiring hospitalization for anti-epileptic loading, as occurred during this event; with multiple confounders (e.g., anesthesia, urinary tract infection (UTI), sleep deprivation). Overall, she has experienced an increase in seizure-free days since dosing.  One SAE (constipation, moderate, grade 2) unrelated to TSHA-102 was reported after TEAE listing cut off. Patient was admitted for irritability and had a medical history of constipation and concurrent non-serious event of parainfluenza virus, which may have been contributory.  The most common AE overall was vomiting (5 TEAEs), a known risk of sirolimus.  Laboratory Measures Liver Function. Patients have experienced no clinically significant liver or cardiac abnormalities. Laboratory evaluations have shown some excursions, particularly in patients with high liver enzyme values (GGT/ALT/AST and AP) at Baseline. Two patients had abnormal liver enzymes at Baseline, consistent with concomitant medication. One patient showed mild (<1.5 x ULN) transient and self-limited ALT and AST elevations, that were not assessed at TEAEs.  Neurofilament light chain (NfL) levels. All four patients have experienced transient NfL increase, consistent with the NfL increase after LP alone, as reported in nonhuman primates in the absence of gene therapy and in a small human study.5-7  NfL increases through Week 4, declining after week 12. MRI Brain and Spine: No findings of inflammation or damage.  SNAPs: No clinically significant changes from Baseline No observed functional changes or clinical correlation with TEAEs.  Relatedness Assessments* Event (MedDRA PT) Total Events (Patients) TSHA-102 Pre-existing Disease Immuno-suppression  Other Cause/ None Any TEAE 34 (4) 10 6 13 9 Pyrexia 2 (2) 2 0 0 0 CSF protein increased 2 (2) 2 0 0 0 Lethargy 2 (2) 2 1 0 1 Vomiting 5 (2) 1 0 3 0 Irritability 4 (2) 1 1 2 0 Clonus 1 1 0 0 0 Seizures 1 1 1 0 0 Listing  5.1 TSHA-102-CL-101 and TSHA-102-CL-102, 05/10/2024. *An event may have more than 1 causality reported. Causality assessments updated per communication from investigator on 06/11/2024. The following TEAEs unrelated to TSHA-102, were  also reported: Myopathy, Agitation, Aphthous Ulcer, Blister, chronic kidney disease,Cystatin C increased, Dermatitis acneiform, Epilepsy, Escherichia UTI,  Gastroenteritis,  Infection, Papular rash, Seizure, Skin ulcer, Stress fracture, Ureteric dilatation Table 2: TEAEs causality and events related to TSHA-102

Taysha Gene Therapies (NASDAQ:TSHA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Taysha Gene Therapies (NASDAQ:TSHA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024